Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
ConclusionsThis study provides evidence for the real-world effectiveness of fremanezumab in treating both high-frequency episodic migraine and chronic migraine, with meaningful and sustained improvements in multiple migraine-related variables. No new safety issue was identified.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: Disability | Genetics | Headache | Italy Health | Migraine | Neurology | Statistics | Study